TargetMol

SW116

Product Code:
 
TAR-T26243
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T26243-100mg100mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26243-500mg500mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
SW116 is used as a fluorescent sigma-2 selective ligand.
CAS:
1421931-13-6
Molecular Weight:
708.95
Purity:
0.98
SMILES:
O=C(OC1CC2N(CCCCCCCCCCNS(=O)(=O)C3=CC=CC=4C3=CC=CC4N(C)C)C(CCC2)C1)NC5=CC(OC)=CC=C5OC

References

S?rensen BS, Knudsen A, Wittrup CF, Nielsen S, Aggerholm-Pedersen N, Busk M, Horsman M, H?yer M, Bouchelouche PN, Overgaard J, Alsner J. The usability of a 15-gene hypoxia classifier as a universal hypoxia profile in various cancer cell types. Radiother Oncol. 2015 Sep;116(3):346-51. doi: 10.1016/j.radonc.2015.06.028. Epub 2015 Jul 10. PubMed PMID: 26169282. Zhu MM, Tong JL, Xu Q, Nie F, Xu XT, Xiao SD, Ran ZH. Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer. PLoS One. 2012;7(8):e41763. doi: 10.1371/journal.pone.0041763. Epub 2012 Aug 1. PubMed PMID: 22870247; PubMed Central PMCID: PMC3411563. Deng C, Xiong J, Gu X, Chen X, Wu S, Wang Z, Wang D, Tu J, Xie J. Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro. Oncotarget. 2017 Jun 13;8(24):38568-38580. doi: 10.18632/oncotarget.16930. PubMed PMID: 28445134; PubMed Central PMCID: PMC5503554. Sun J, Ren SZ, Lu XY, Li JJ, Shen FQ, Xu C, Zhu HL. Discovery of a series of 1,3,4-oxadiazole-2(3H)-thione derivatives containing piperazine skeleton as potential FAK inhibitors. Bioorg Med Chem. 2017 May 1;25(9):2593-2600. doi: 10.1016/j.bmc.2017.03.038. Epub 2017 Mar 19. PubMed PMID: 28363444.